Pharmaceutical company Alkem Laboratories Ltd has received an allotment letter dated March 18, 2026, from DMIC Vikram Udyogpuri Ltd for approximately 30 acres of land in Phase 2 of the industrial area in Ujjain, Madhya Pradesh. According to reports from CNBC TV18, the company's board of directors has approved an investment of up to ₹533 crore for the project, which will be executed in a phased manner. The land has been allotted in the Industrial Area developed by DMIC Vikram Udyogpuri Ltd in Ujjain, with the proposed facility being a formulation manufacturing unit aimed at expanding the company's manufacturing capabilities and enhancing production capacity.
Alkem Laboratories reported a 5% year-on-year rise in net profit at ₹626 crore in the December quarter, compared to ₹595 crore in the corresponding quarter of the previous year. As reported by CNBC TV18, revenue from operations was up marginally by 1.5% year-on-year to ₹3,374 crore in the quarter under review, against ₹3,324 crore in the same quarter last year. Earnings before interest, tax, depreciation, and amortisation (EBITDA) climbed 7.4% to ₹759 crore, compared to ₹707.4 crore in the year-ago period, with EBITDA margin expanding by 120 basis points to 22.5%.
The company's international operations showed strong performance during Q3FY25. According to CNBC TV18, overall contribution of the US sales to total sales stood at 19.1% in the quarter, while other international market sales contributed 9.8% to total sales. The company received two approvals from the USFDA during the quarter, including one tentative approval. Alkem Laboratories maintains a presence mainly in Latin America, Australia and Europe.
Shares of Alkem Laboratories Ltd ended at ₹5,331.60, down by ₹2.50, or 0.047%, on the BSE on Wednesday, as reported by CNBC TV18. The stock movement occurred despite the company's significant investment announcement and positive quarterly results.
